Literature DB >> 23775647

V. Molecular classification and risk stratification of myeloma.

P Leif Bergsagel1, Marta Chesi.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23775647      PMCID: PMC3941196          DOI: 10.1002/hon.2065

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


× No keyword cloud information.
  15 in total

1.  The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells.

Authors:  Eva Martinez-Garcia; Relja Popovic; Dong-Joon Min; Steve M M Sweet; Paul M Thomas; Leonid Zamdborg; Aaron Heffner; Christine Will; Laurence Lamy; Louis M Staudt; David L Levens; Neil L Kelleher; Jonathan D Licht
Journal:  Blood       Date:  2010-10-25       Impact factor: 22.113

2.  BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

Authors:  Jake E Delmore; Ghayas C Issa; Madeleine E Lemieux; Peter B Rahl; Junwei Shi; Hannah M Jacobs; Efstathios Kastritis; Timothy Gilpatrick; Ronald M Paranal; Jun Qi; Marta Chesi; Anna C Schinzel; Michael R McKeown; Timothy P Heffernan; Christopher R Vakoc; P Leif Bergsagel; Irene M Ghobrial; Paul G Richardson; Richard A Young; William C Hahn; Kenneth C Anderson; Andrew L Kung; James E Bradner; Constantine S Mitsiades
Journal:  Cell       Date:  2011-09-01       Impact factor: 41.582

3.  Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013.

Authors:  Joseph R Mikhael; David Dingli; Vivek Roy; Craig B Reeder; Francis K Buadi; Suzanne R Hayman; Angela Dispenzieri; Rafael Fonseca; Taimur Sher; Robert A Kyle; Yi Lin; Stephen J Russell; Shaji Kumar; P Leif Bergsagel; Steven R Zeldenrust; Nelson Leung; Matthew T Drake; Prashant Kapoor; Stephen M Ansell; Thomas E Witzig; John A Lust; Robert J Dalton; Morie A Gertz; A Keith Stewart; Keith Stewart; S Vincent Rajkumar; Asher Chanan-Khan; Martha Q Lacy
Journal:  Mayo Clin Proc       Date:  2013-04       Impact factor: 7.616

4.  Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics.

Authors:  Shaji Kumar; Rafael Fonseca; Rhett P Ketterling; Angela Dispenzieri; Martha Q Lacy; Morie A Gertz; Suzanne R Hayman; Francis K Buadi; David Dingli; Ryan A Knudson; Alexandra Greenberg; Stephen J Russell; Steven R Zeldenrust; John A Lust; Robert A Kyle; Leif Bergsagel; S Vincent Rajkumar
Journal:  Blood       Date:  2012-01-10       Impact factor: 22.113

5.  NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming.

Authors:  Alex J Kuo; Peggie Cheung; Kaifu Chen; Barry M Zee; Mitomu Kioi; Josh Lauring; Yuanxin Xi; Ben Ho Park; Xiaobing Shi; Benjamin A Garcia; Wei Li; Or Gozani
Journal:  Mol Cell       Date:  2011-11-18       Impact factor: 17.970

6.  Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

Authors:  Jonathan J Keats; Rafael Fonseca; Marta Chesi; Roelandt Schop; Angela Baker; Wee-Joo Chng; Scott Van Wier; Rodger Tiedemann; Chang-Xin Shi; Michael Sebag; Esteban Braggio; Travis Henry; Yuan-Xiao Zhu; Homer Fogle; Tammy Price-Troska; Gregory Ahmann; Catherine Mancini; Leslie A Brents; Shaji Kumar; Philip Greipp; Angela Dispenzieri; Barb Bryant; George Mulligan; Laurakay Bruhn; Michael Barrett; Riccardo Valdez; Jeff Trent; A Keith Stewart; John Carpten; P Leif Bergsagel
Journal:  Cancer Cell       Date:  2007-08       Impact factor: 31.743

7.  Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development.

Authors:  Flavia Pichiorri; Sung-Suk Suh; Alberto Rocci; Luciana De Luca; Cristian Taccioli; Ramasamy Santhanam; Wenchao Zhou; Don M Benson; Craig Hofmainster; Hansjuerg Alder; Michela Garofalo; Gianpiero Di Leva; Stefano Volinia; Huey-Jen Lin; Danilo Perrotti; Michael Kuehl; Rami I Aqeilan; Antonio Palumbo; Carlo M Croce
Journal:  Cancer Cell       Date:  2010-10-19       Impact factor: 31.743

8.  Initial genome sequencing and analysis of multiple myeloma.

Authors:  Michael A Chapman; Michael S Lawrence; Jonathan J Keats; Kristian Cibulskis; Carrie Sougnez; Anna C Schinzel; Christina L Harview; Jean-Philippe Brunet; Gregory J Ahmann; Mazhar Adli; Kenneth C Anderson; Kristin G Ardlie; Daniel Auclair; Angela Baker; P Leif Bergsagel; Bradley E Bernstein; Yotam Drier; Rafael Fonseca; Stacey B Gabriel; Craig C Hofmeister; Sundar Jagannath; Andrzej J Jakubowiak; Amrita Krishnan; Joan Levy; Ted Liefeld; Sagar Lonial; Scott Mahan; Bunmi Mfuko; Stefano Monti; Louise M Perkins; Robb Onofrio; Trevor J Pugh; S Vincent Rajkumar; Alex H Ramos; David S Siegel; Andrey Sivachenko; A Keith Stewart; Suzanne Trudel; Ravi Vij; Douglas Voet; Wendy Winckler; Todd Zimmerman; John Carpten; Jeff Trent; William C Hahn; Levi A Garraway; Matthew Meyerson; Eric S Lander; Gad Getz; Todd R Golub
Journal:  Nature       Date:  2011-03-24       Impact factor: 49.962

9.  Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma.

Authors:  W-J Chng; G F Huang; T H Chung; S B Ng; N Gonzalez-Paz; T Troska-Price; G Mulligan; M Chesi; P L Bergsagel; R Fonseca
Journal:  Leukemia       Date:  2011-04-05       Impact factor: 11.528

10.  MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites.

Authors:  Huadong Pei; Lindsey Zhang; Kuntian Luo; Yuxin Qin; Marta Chesi; Frances Fei; P Leif Bergsagel; Liewei Wang; Zhongsheng You; Zhenkun Lou
Journal:  Nature       Date:  2011-02-03       Impact factor: 49.962

View more
  11 in total

1.  Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma.

Authors:  J R Sawyer; E Tian; J D Shaughnessy; J Epstein; C M Swanson; C Stangeby; C L Hale; L Parr; M Lynn; G Sammartino; J L Lukacs; C Stein; C Bailey; M Zangari; F E Davies; F Van Rhee; B Barlogie; G J Morgan
Journal:  Leukemia       Date:  2016-10-03       Impact factor: 11.528

2.  Three-dimensional Nuclear Telomere Organization in Multiple Myeloma.

Authors:  Ludger Klewes; Rhea Vallente; Eric Dupas; Carolin Brand; Dietrich Grün; Amanda Guffei; Chirawadee Sathitruangsak; Julius A Awe; Alexandra Kuzyk; Daniel Lichtensztejn; Pille Tammur; Tiiu Ilus; Anu Tamm; Mari Punab; Morel Rubinger; Adebayo Olujohungbe; Sabine Mai
Journal:  Transl Oncol       Date:  2013-12-01       Impact factor: 4.243

3.  Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies.

Authors:  Simona Caltagirone; Marina Ruggeri; Simona Aschero; Milena Gilestro; Daniela Oddolo; Francesca Gay; Sara Bringhen; Caterina Musolino; Luca Baldini; Pellegrino Musto; Maria T Petrucci; Gianluca Gaidano; Roberto Passera; Benedetto Bruno; Antonio Palumbo; Mario Boccadoro; Paola Omedè
Journal:  Haematologica       Date:  2014-07-11       Impact factor: 9.941

Review 4.  Towards Stratified Medicine in Plasma Cell Myeloma.

Authors:  Philip Egan; Stephen Drain; Caroline Conway; Anthony J Bjourson; H Denis Alexander
Journal:  Int J Mol Sci       Date:  2016-10-21       Impact factor: 5.923

5.  Observation on frequency & clinico-pathological significance of various cytogenetic risk groups in multiple myeloma: an experience from India.

Authors:  Pratibha S Kadam Amare; Hemani Jain; Shraddha Nikalje; Manju Sengar; Hari Menon; Nitin Inamdar; P G Subramanian; Sumeet Gujral; Tanuja Shet; Sridhar Epari; Reena Nair
Journal:  Indian J Med Res       Date:  2016-10       Impact factor: 2.375

Review 6.  Germline Risk Contribution to Genomic Instability in Multiple Myeloma.

Authors:  Siegfried Janz; Fenghuang Zhan; Fumou Sun; Yan Cheng; Michael Pisano; Ye Yang; Hartmut Goldschmidt; Parameswaran Hari
Journal:  Front Genet       Date:  2019-05-08       Impact factor: 4.599

7.  Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations.

Authors:  Charlotte Pawlyn; Lorenzo Melchor; Alex Murison; Christopher P Wardell; Annamaria Brioli; Eileen M Boyle; Martin F Kaiser; Brian A Walker; Dil B Begum; Nasrin B Dahir; Paula Proszek; Walter M Gregory; Mark T Drayson; Graham H Jackson; Fiona M Ross; Faith E Davies; Gareth J Morgan
Journal:  Blood       Date:  2014-11-26       Impact factor: 25.476

8.  The ubiquitin-conjugating enzyme UBE2O modulates c-Maf stability and induces myeloma cell apoptosis.

Authors:  Yujia Xu; Zubin Zhang; Jie Li; Jiefei Tong; Biyin Cao; Paul Taylor; Xiaowen Tang; Depei Wu; Michael F Moran; Yuanying Zeng; Xinliang Mao
Journal:  J Hematol Oncol       Date:  2017-07-03       Impact factor: 17.388

9.  Hyperhaploid karyotypes in multiple myeloma.

Authors:  Jeffrey R Sawyer; Gareth J Morgan
Journal:  Oncotarget       Date:  2017-09-14

10.  Multiple Myeloma Exemplifies a Model of Cancer Based on Tissue Disruption as the Initiator Event.

Authors:  Jean-Pascal Capp; Régis Bataille
Journal:  Front Oncol       Date:  2018-09-10       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.